Regen BioPharma Inc logo
RGBPP

Regen BioPharma Inc

Last Price US$0.005 Latest stored quote
Market Cap US$104.5m Company size context
7D Performance 108.33% Past 7 days
1Y Performance N/A Past 12 months
Model Rating Not rated Insufficient reported history for the model
Loading Mave Thesis research outlook

Dashboard Funda..tals Prediction Screener Map

Regen BioPharma Inc Overview

Industry: Biotechnology

Sector: Healthcare

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is also involved in the development of its products, and therapies, including HemaXellarate, a cellular composition of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. Regen BioPharma, Inc. was incorporated in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The com Read More

Reported Results

No latest earnings report cached yet

Run the EDGAR earnings refresh to load the latest company-filed earnings release, 10-Q, 10-K, or transcript exhibit for this ticker.

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

SEC financial statements are temporarily unavailable.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Regen BioPharma Inc logo

Regen BioPharma Inc

US$0.005

US$104.5m

108.33%

N/A